Skip to content

Nitrofurantoin

FDA-approved product (tablet, oral), marketed as Furadantin, Furalan, Nitrofurantoin and 3 more.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nitrofurantoin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Cystitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nitrofuran derivatives
FDA pharmacologic class
Nitrofuran Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XE01; WHO ATC J01XE51; FDA class Nitrofuran Antibacterial

Repurposing investigation

Nitrofurantoin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli31.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis92.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 4 lab records
  • M. tuberculosis: measured active in 1 of 2 lab records
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nitrofurantoin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prophylactic Antibiotics for Outpatient Urethral Bulking

    NCT07501065 · start 2026-08

    Registered record
    Registry ID
    NCT07501065
    Conditions
    Urinary Tract Infections; Stress Urinary Incontinence; Urinary Incontinence
    Interventions
    Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-08
    Completion
    2028-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Stress Urinary Incontinence; Urinary Incontinence
    InterventionBactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
    PhasePhase 4
    Registry statusRecruiting
  • Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms

    NCT07648290 · start 2026-07-31

    Registered record
    Registry ID
    NCT07648290
    Conditions
    Overactive Bladder
    Interventions
    Macrobid® Capsules 100 mg; Standard Medical Care (SMC)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2026-07-31
    Completion
    2028-03-31
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    InterventionMacrobid® Capsules 100 mg; Standard Medical Care (SMC)
    PhaseEarly phase 1
    Registry statusRecruiting
  • Pediatric Pilonidal Sinus Surgical Treatment

    NCT07369921 · start 2026-04-30

    Registered record
    Registry ID
    NCT07369921
    Conditions
    Surgery; Pilonidal Sinus; Pediatric
    Interventions
    Crystallized Phenol Applied
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-04-30
    Completion
    2026-05-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgery; Pilonidal Sinus; Pediatric
    InterventionCrystallized Phenol Applied
    PhaseNot applicable
    Registry statusRecruiting
  • Randomized Controlled Trial of Different Antibiotic Duration Prior to Prostate Enucleation Surgery

    NCT07209150 · start 2026-01-01

    Registered record
    Registry ID
    NCT07209150
    Conditions
    BPH With Urinary Obstruction; Antibiotic Prophylaxis
    Interventions
    antibiotic prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-01-01
    Completion
    2028-07-15
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH With Urinary Obstruction; Antibiotic Prophylaxis
    Interventionantibiotic prophylaxis
    PhasePhase 3
    Registry statusNot yet recruiting
  • Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries

    NCT06723392 · start 2025-12-08

    Registered record
    Registry ID
    NCT06723392
    Conditions
    Preterm Birth; Small for Gestational Age (SGA); Stillbirth; Bacteriuria (Asymptomatic) in Pregnancy
    Interventions
    Oral nitrofurantoin monohydrate/macrocrystals; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-08
    Completion
    2028-11
    Enrolment
    1,134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Birth; Small for Gestational Age (SGA); Stillbirth; Bacteriuria (Asymptomatic) in Pregnancy
    InterventionOral nitrofurantoin monohydrate/macrocrystals; Placebo
    PhasePhase 3
    Registry statusRecruiting
  • Urine Alkalinization for UTI in Women: RCT

    NCT07202832 · start 2025-10-15

    Registered record
    Registry ID
    NCT07202832
    Conditions
    UTI - Urinary Tract Infection
    Interventions
    potassium citrate; Nitrofurantoin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-10-15
    Completion
    2027-01-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUTI - Urinary Tract Infection
    Interventionpotassium citrate; Nitrofurantoin
    PhaseNot applicable
    Registry statusNot yet recruiting
  • Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)

    NCT06706362 · start 2025-09-15

    Registered record
    Registry ID
    NCT06706362
    Conditions
    Stress Urinary Incontinence
    Interventions
    Bactrim or Macrobid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-09-15
    Completion
    2027-10-15
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Urinary Incontinence
    InterventionBactrim or Macrobid; Placebo
    PhasePhase 4
    Registry statusRecruiting
  • Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis

    NCT07186465 · start 2025-09-11

    Registered record
    Registry ID
    NCT07186465
    Conditions
    Cystitis, Recurrent; Urinary Tract Infections
    Interventions
    Nitrofurantoin; Gynoflor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-09-11
    Completion
    2026-08-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystitis, Recurrent; Urinary Tract Infections
    InterventionNitrofurantoin; Gynoflor
    PhasePhase 4
    Registry statusRecruiting
  • Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

    NCT07025044 · start 2025-09-03

    Registered record
    Registry ID
    NCT07025044
    Conditions
    Overactive Bladder (OAB); Urge Incontinence
    Interventions
    onabotulinum toxin type a
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-03
    Completion
    2026-06-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder (OAB); Urge Incontinence
    Interventiononabotulinum toxin type a
    PhaseNot recorded
    Registry statusRecruiting
  • Comparison of Inter-appointment Pain Reduction During Root Canal Treatment in Symptomatic Apical Periodontitis by Using Intracanal Medicaments; Chlorhexidine Gel and Single Antibiotic Paste Nitrofurantoin

    NCT07198919 · start 2025-05-20

    Registered record
    Registry ID
    NCT07198919
    Conditions
    Intracanal Medicament
    Interventions
    Chlorhexidine gel; Nitrofurantoin 100 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Enrolling by invitation
    Start
    2025-05-20
    Completion
    2025-11-30
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracanal Medicament
    InterventionChlorhexidine gel; Nitrofurantoin 100 MG
    PhasePhase 1 / Phase 2
    Registry statusEnrolling by invitation
  • Intravesical Gentamicin to Prevent Recurrent UTI

    NCT06332781 · start 2025-04-28

    Registered record
    Registry ID
    NCT06332781
    Conditions
    Recurrent Uti
    Interventions
    Gentamicin; Nitrofurantoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-04-28
    Completion
    2026-03-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Uti
    InterventionGentamicin; Nitrofurantoin
    PhasePhase 4
    Registry statusCompleted
  • Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

    NCT06709196 · start 2025-01-07

    Registered record
    Registry ID
    NCT06709196
    Conditions
    Cystectomy; Bladder Cancer Requiring Cystectomy; Postoperative Infections; Antibiotic Prophylaxis; Ileal Conduit
    Interventions
    Pivmecillinam; Pivmecillinam; Amoxicillin clavulanic acid; Amoxicillin; Cefuroxime; Ciprofloxacin; Linezolid; Nitrofurantoin; Trimethoprim; Sulfamethoxazole trimethoprim; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-07
    Completion
    2027-01
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystectomy; Bladder Cancer Requiring Cystectomy; Postoperative Infections; Antibiotic Prophylaxis +1 more
    InterventionPivmecillinam; Pivmecillinam; Amoxicillin clavulanic acid; Amoxicillin +7 more
    PhasePhase 4
    Registry statusRecruiting
  • COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN

    NCT06518291 · start 2025-01

    Registered record
    Registry ID
    NCT06518291
    Conditions
    Urinary Tract Infections
    Interventions
    Nitrofurantoin 100 MG; Fosfomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2025-01
    Completion
    2025-06
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionNitrofurantoin 100 MG; Fosfomycin
    PhasePhase 4
    Registry statusUnknown
  • Role of Prophylactic Postoperative Antibiotics in HoLEP

    NCT05274672 · start 2023-03-01

    Registered record
    Registry ID
    NCT05274672
    Conditions
    Benign Prostatic Hyperplasia; Urinary Tract Infections
    Interventions
    Nitrofurantoin; Cephalexin; Sulfamethoxazole Trimethoprim Combination; Ciprofloxacin; Holmium Laser Enucleation of prostate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2023-03-01
    Completion
    2025-02-20
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Urinary Tract Infections
    InterventionNitrofurantoin; Cephalexin; Sulfamethoxazole Trimethoprim Combination; Ciprofloxacin +1 more
    PhasePhase 4
    Registry statusWithdrawn
  • Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

    NCT05719285 · start 2022-12-06

    Registered record
    Registry ID
    NCT05719285
    Conditions
    Overactive Bladder; Overactive Bladder Syndrome; Urge Incontinence; Urinary Incontinence, Urge
    Interventions
    Single-Dose Antibiotic; Multi-Dose Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-12-06
    Completion
    2023-06-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Overactive Bladder Syndrome; Urge Incontinence; Urinary Incontinence, Urge
    InterventionSingle-Dose Antibiotic; Multi-Dose Antibiotic
    PhasePhase 4
    Registry statusCompleted